FDA approves Genentech's Hemlibra for hemophilia A

FDA approved once-weekly subcutaneous Hemlibra emicizumab-kxwh from the Genentech Inc. unit of Roche (SIX:ROG;

Read the full 143 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE